191 related articles for article (PubMed ID: 31221545)
21. Integration of Bone and Computed Tomography Scans to Assess Bone Metastasis in Metastatic Castration-Resistant Prostate Cancer.
Parker SJ; Pond GR; Agarwal N; Alex A; Heilbrun ME; Sonpavde G
Clin Genitourin Cancer; 2017 Feb; 15(1):53-59. PubMed ID: 27338517
[TBL] [Abstract][Full Text] [Related]
22. The value of quantitative analysis in
Lapa P; Marques M; Costa G; Lima JP
Rev Esp Med Nucl Imagen Mol; 2017; 36(2):78-84. PubMed ID: 27793635
[TBL] [Abstract][Full Text] [Related]
23. The Prognostic Value of Quantitative Bone SPECT/CT Before
Dittmann H; Kaltenbach S; Weissinger M; Fiz F; Martus P; Pritzkow M; Kupferschlaeger J; la Fougère C
J Nucl Med; 2021 Jan; 62(1):48-54. PubMed ID: 32444369
[TBL] [Abstract][Full Text] [Related]
24. Reproducibility and Repeatability of Semiquantitative
Vargas HA; Kramer GM; Scott AM; Weickhardt A; Meier AA; Parada N; Beattie BJ; Humm JL; Staton KD; Zanzonico PB; Lyashchenko SK; Lewis JS; Yaqub M; Sosa RE; van den Eertwegh AJ; Davis ID; Ackermann U; Pathmaraj K; Schuit RC; Windhorst AD; Chua S; Weber WA; Larson SM; Scher HI; Lammertsma AA; Hoekstra OS; Morris MJ
J Nucl Med; 2018 Oct; 59(10):1516-1523. PubMed ID: 29626121
[No Abstract] [Full Text] [Related]
25. Prognostic role of 11C-choline PET/CT scan in patients with metastatic castrate resistant prostate cancer undergoing primary docetaxel chemotherapy.
Jimbo M; Andrews JR; Ahmed ME; Dundar A; Karnes RJ; Bryce AH; Kendi AT; Kwon ED; Lowe VJ; Bold MS
Prostate; 2022 Jan; 82(1):41-48. PubMed ID: 34633087
[TBL] [Abstract][Full Text] [Related]
26. Prospective Study of Serial
Peterson LM; O'Sullivan J; Wu QV; Novakova-Jiresova A; Jenkins I; Lee JH; Shields A; Montgomery S; Linden HM; Gralow J; Gadi VK; Muzi M; Kinahan P; Mankoff D; Specht JM
J Nucl Med; 2018 Dec; 59(12):1823-1830. PubMed ID: 29748233
[TBL] [Abstract][Full Text] [Related]
27.
Wondergem M; van der Zant FM; Knol RJJ; Burgers AMG; Bos SD; de Jong IJ; Pruim J
World J Urol; 2018 Jan; 36(1):27-34. PubMed ID: 29043431
[TBL] [Abstract][Full Text] [Related]
28. Comparison of NaF and FDG PET/CT for assessment of treatment response in castration-resistant prostate cancers with osseous metastases.
Simoncic U; Perlman S; Liu G; Staab MJ; Straus JE; Jeraj R
Clin Genitourin Cancer; 2015 Feb; 13(1):e7-e17. PubMed ID: 25128349
[TBL] [Abstract][Full Text] [Related]
29. Automated classification of benign and malignant lesions in
Perk T; Bradshaw T; Chen S; Im HJ; Cho S; Perlman S; Liu G; Jeraj R
Phys Med Biol; 2018 Nov; 63(22):225019. PubMed ID: 30457118
[TBL] [Abstract][Full Text] [Related]
30.
Hazelton J; Kim S; Boerner JL; Podgorski I; Perk T; Cackowski F; Aoun HD; Heath EI
Prostate; 2023 Sep; 83(12):1193-1200. PubMed ID: 37211866
[TBL] [Abstract][Full Text] [Related]
31. Determination of Skeletal Tumor Burden on 18F-Fluoride PET/CT.
Rohren EM; Etchebehere EC; Araujo JC; Hobbs BP; Swanston NM; Everding M; Moody T; Macapinlac HA
J Nucl Med; 2015 Oct; 56(10):1507-12. PubMed ID: 26135112
[TBL] [Abstract][Full Text] [Related]
32. Optimizing an 18F-NaF and 18F-FDG cocktail for PET assessment of metastatic castration-resistant prostate cancer.
Simoncic U; Perlman S; Liu G; Jeraj R
Nucl Med Commun; 2015 Dec; 36(12):1174-80. PubMed ID: 26378490
[TBL] [Abstract][Full Text] [Related]
33. Opportunistic skeletal muscle metrics as prognostic tools in metastatic castration-resistant prostate cancer patients candidates to receive Radium-223.
Bauckneht M; Lai R; D'Amico F; Miceli A; Donegani MI; Campi C; Schenone D; Raffa S; Chiola S; Lanfranchi F; Rebuzzi SE; Zanardi E; Cremante M; Marini C; Fornarini G; Morbelli S; Piana M; Sambuceti G
Ann Nucl Med; 2022 Apr; 36(4):373-383. PubMed ID: 35044592
[TBL] [Abstract][Full Text] [Related]
34.
Papadakis GZ; Manikis GC; Karantanas AH; Florenzano P; Bagci U; Marias K; Collins MT; Boyce AM
J Bone Miner Res; 2019 Sep; 34(9):1619-1631. PubMed ID: 31116487
[TBL] [Abstract][Full Text] [Related]
35. Prediction of Response to Tumor Necrosis Value-α Blocker Is Suggested by
Kim K; Son SM; Goh TS; Pak K; Kim IJ; Lee JS; Kim SJ
AJR Am J Roentgenol; 2020 Jun; 214(6):1352-1358. PubMed ID: 32286869
[No Abstract] [Full Text] [Related]
36. A Prospective Study Comparing
Löfgren J; Mortensen J; Rasmussen SH; Madsen C; Loft A; Hansen AE; Oturai P; Jensen KE; Mørk ML; Reichkendler M; Højgaard L; Fischer BM
J Nucl Med; 2017 Nov; 58(11):1778-1785. PubMed ID: 28798033
[TBL] [Abstract][Full Text] [Related]
37. Assessment of skeletal tumour burden on 18F-NaF PET/CT using a new quantitative method.
Lapa P; Marques M; Costa G; Iagaru A; Pedroso de Lima J
Nucl Med Commun; 2017 Apr; 38(4):325-332. PubMed ID: 28230714
[TBL] [Abstract][Full Text] [Related]
38. Whole-body 18F-fluorocholine (FCH) PET/CT and MRI of the spine for monitoring patients with castration-resistant prostate cancer metastatic to bone: a pilot study.
Balogova S; Zakoun JB; Michaud L; Khalil A; Tassart M; Esteso A; Kerrou K; Huchet V; Carette MF; Lotz JP; Talbot JN
Clin Nucl Med; 2014 Nov; 39(11):951-9. PubMed ID: 25140552
[TBL] [Abstract][Full Text] [Related]
39. Assessment of the bone scan index in a randomized placebo-controlled trial of tasquinimod in men with metastatic castration-resistant prostate cancer (mCRPC).
Armstrong AJ; Kaboteh R; Carducci MA; Damber JE; Stadler WM; Hansen M; Edenbrandt L; Forsberg G; Nordle Ö; Pili R; Morris MJ
Urol Oncol; 2014 Nov; 32(8):1308-16. PubMed ID: 25240761
[TBL] [Abstract][Full Text] [Related]
40. Feasibility of Global Assessment of Bone Metastases in Prostate Cancer with
Koa B; Raynor WY; Park PSU; Borja AJ; Singhal S; Kuang A; Zhang V; Werner TJ; Alavi A; Revheim ME
PET Clin; 2022 Oct; 17(4):631-640. PubMed ID: 36229105
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
